Sandoz Issues Mid-term Outlook For 2025-2030; Unveils Bio100 Ambition
(RTTNews) - Sandoz (SDZ.SW) reaffirmed its prevailing mid-term outlook to 2028. The company introduced a new mid-term outlook for 2025 to 2030, targeting mid-to-high single-digit percentage growth in average annual net sales at constant currencies and a core EBITDA margin of 25-2
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.